Tolerability of Antiseizure Medications in Individuals With Newly Diagnosed Epilepsy
4 June, 2020
Bshra Ali A. Alsfouk, PhD; Martin J. Brodie, MD; Matthew Walters, MD; et al
JAMA Neurology February 24, 2020 2020;77(5):574-581. doi:10.1001/jamaneurol.2020.0032
Has the overall tolerability of antiseizure medications (ASMs) improved after the introduction of more than a dozen second-generation ASMs in the past 3 decades?
In this 30-year longitudinal cohort study of 1795 individuals with newly diagnosed and treated epilepsy, the intolerable adverse effect rate observed was not improved despite the increased using of second-generations ASMs.
Efficacy and tolerability are 2 sides of the same coin in achieving successful epilepsy treatment; to improve the overall effectiveness of ASM treatment, future drug development should not only focus on seizure control, but also tolerability and safety profile.
Subscribe to the ILAE Newsletter
To subscribe, please click on the button below.
Please send me information about ILAE activities and other
information of interest to the epilepsy community